Finally, it is important to realize the normalization of both tumor vessels and ECM is a transient event that is strongly dictated by the dose and duration of the therapeutic agents given and by the characteristics of the tumor itself.10, 23, 24 Investigations have already been conducted to explore vascular normalization strategies beyond disrupting the VEGF/VEGFR axis. The gene discussed is VEGFA; the disease is neoplasm.